Clinical Trials
15
Active:1
Completed:14
Trial Phases
3 Phases
Phase 1:7
Phase 2:3
Phase 3:5
Drug Approvals
1
EMA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (46.7%)Phase 3
5 (33.3%)Phase 2
3 (20.0%)Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women
Phase 2
Active, not recruiting
- Conditions
- Sexual Dysfunction, Physiological
- Interventions
- Drug: 20 mg estetrol monohydrateOther: Placebo
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Estetra
- Target Recruit Count
- 82
- Registration Number
- NCT06308614
- Locations
- 🇺🇸
Estetra Study Site, Seattle, Washington, United States
Effect of Estetrol Monohydrate (E4) on QTc Interval
Phase 1
Completed
- Conditions
- Prolonged QTc Interval
- Interventions
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Estetra
- Target Recruit Count
- 32
- Registration Number
- NCT04819906
- Locations
- 🇺🇸
QPS Miami, Miami, Florida, United States
Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents
Phase 3
Completed
- Conditions
- Safety
- Interventions
- Drug: E4/DRSP 15/3 mg combined tablet
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Estetra
- Target Recruit Count
- 145
- Registration Number
- NCT04792385
- Locations
- 🇪🇪
KVL Medical Office/KVL Arstikabinet, Parnu, Estonia
🇪🇪East-Tallinn Central Hospital, Tallinn, Estonia
🇪🇪Sexual Health Clinic, Tallinn, Tallinn, Estonia
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
Phase 3
Completed
- Conditions
- Vasomotor SymptomsMenopausal Symptoms
- Interventions
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Estetra
- Target Recruit Count
- 1570
- Registration Number
- NCT04209543
- Locations
- 🇬🇧
Estetra Study Site, Orpington, United Kingdom
🇺🇸Precision Trials AZ, LLC, Phoenix, Arizona, United States
🇺🇸Noble Clinical Research, Tucson, Arizona, United States
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women
Phase 3
Completed
- Conditions
- Vasomotor SymptomsMenopausal Symptoms
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Estetra
- Target Recruit Count
- 1015
- Registration Number
- NCT04090957
- Locations
- 🇨🇦
Estetra Study Site, Waterloo, Canada
- Prev
- 1
- 2
- 3
- Next
News
No news found